Business Description
Bone Biologics Corp
NAICS : 325412
SIC : 3842
ISIN : US0980702049
Description
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.96 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 19.5 | |||||
3-Year EPS without NRI Growth Rate | 38.1 | |||||
3-Year FCF Growth Rate | -0.7 | |||||
Future 3-5Y EPS without NRI Growth Rate | 45.56 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 40.95 | |||||
9-Day RSI | 38.78 | |||||
14-Day RSI | 37.85 | |||||
6-1 Month Momentum % | -64.22 | |||||
12-1 Month Momentum % | -86.22 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 23.27 | |||||
Quick Ratio | 23.27 | |||||
Cash Ratio | 19.56 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -118.6 | |||||
Shareholder Yield % | -447.15 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -162.03 | |||||
ROA % | -113.22 | |||||
ROIC % | -1201.91 | |||||
ROC (Joel Greenblatt) % | -6088.98 | |||||
ROCE % | -190.67 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.33 | |||||
Price-to-Tangible-Book | 0.33 | |||||
EV-to-EBIT | 0.27 | |||||
EV-to-EBITDA | 0.27 | |||||
EV-to-FCF | 0.2 | |||||
Price-to-Net-Current-Asset-Value | 0.33 | |||||
Price-to-Net-Cash | 0.39 | |||||
Earnings Yield (Greenblatt) % | 370.37 | |||||
FCF Yield % | -732.02 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BBLG
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bone Biologics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -22.611 | ||
Beta | -0.13 | ||
Volatility % | 77.44 | ||
14-Day RSI | 37.85 | ||
14-Day ATR ($) | 0.143676 | ||
20-Day SMA ($) | 1.227065 | ||
12-1 Month Momentum % | -86.22 | ||
52-Week Range ($) | 1 - 12.32 | ||
Shares Outstanding (Mil) | 1.1 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Bone Biologics Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Bone Biologics Corp Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Bone Biologics Corp Frequently Asked Questions
What is Bone Biologics Corp(BBLG)'s stock price today?
The current price of BBLG is $1.18. The 52 week high of BBLG is $12.32 and 52 week low is $1.00.
When is next earnings date of Bone Biologics Corp(BBLG)?
The next earnings date of Bone Biologics Corp(BBLG) is 2024-08-14 Est..
Does Bone Biologics Corp(BBLG) pay dividends? If so, how much?
Bone Biologics Corp(BBLG) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |